Biocon Biologics, a subsidiary of Biocon, and Viatris Inc. today
announced the U.S. launch of interchangeable biosimilars SEMGLEE
(insulin glargineyfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. Both biosimilar products are available in vial and prefilled pen presentations and are interchangeable for the reference
brand, LANTUS(insulin glargine), allowing for substitution at the pharmacy counter.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
